Baseline urate level and renal function predict outcomes of urate-lowering therapy using low doses of febuxostat and benzbromarone: a prospective, randomized controlled study in a Chinese primary gout cohort

Table 2 Major clinical parameters during the trial

	Baseline	4 weeks	8 weeks	12 weeks
sUA, μmol/L
Febuxostat	561.10 ± 71.63	405.43 ± 78.20^##	429.41 ± 94.71^##	404.27 ± 81.10^##
Benzbromarone	554.90 ± 66.73	381.58 ± 92.8^##	400.57 ± 79.91^##	390.91 ± 92.87^##
CCr, mL/min
Febuxostat	105.93 ± 30.61	108.17 ± 32.14	108.61 ± 30.73	110.87 ± 30.93^##,*
Benzbromarone	108.86 ± 29.12	108.25 ± 27.27	108.15 ± 28.41	108.08 ± 28.78
Cr, μmol/L
Febuxostat	84.21 ± 15.10	82.39 ± 14.65#	83.38 ± 14.55	80.83 ± 15.13^##,*
Benzbromarone	81.13 ± 12.19	81.63 ± 12.03	79.83 ± 9.82	82.14 ± 12.48
BUN, mmol/L
Febuxostat	5.56 ± 1.21*	5.66 ± 1.19	5.69 ± 1.39	5.59 ± 1.45
Benzbromarone	5.02 ± 1.40	4.84 ± 1.33	5.00 ± 1.36	5.83 ± 7.90
TG, mmol/L
Febuxostat	1.70 ± 0.65	1.98 ± 0.85^#,**	2.03 ± 1.15^#,*	1.97 ± 0.89*
Benzbromarone	1.93 ± 0.93	1.81 ± 0.89	1.95 ± 1.04	1.87 ± 0.85
TC, mmol/L
Febuxostat	4.95 ± 0.93	4.94 ± 0.95	4.89 ± 0.88	5.02 ± 0.87
Benzbromarone	5.21 ± 0.98	5.12 ± 0.91	5.27 ± 0.92	5.20 ± 0.88
ALT, U/L
Febuxostat	32.45 ± 15.96	43.77 ± 22.10^##,**	42.73 ± 24.13^##,**	42.88 ± 24.20^##,*
Benzbromarone	27.74 ± 13.87	29.96 ± 19.74	28.05 ± 15.18	30.08 ± 20.94
AST, U/L
Febuxostat	22.90 ± 11.38	26.97 ± 11.22^##,*	25.365 ± 7.88^##	27.32 ± 14.59^##,**
Benzbromarone	22.16 ± 6.87	22.88 ± 9.76	22.21 ± 7.63	22.75 ± 8.64
GLU, mmol/L
Febuxostat	5.76 ± 0.57	5.63 ± 0.60	5.73 ± 0.66	5.74 ± 0.75
Benzbromarone	5.76 ± 0.93	5.67 ± 1.03	5.65 ± 0.59	5.80 ± 0.94

Data given as mean ± SEM. *P ≤ 0.05, **P ≤ 0.01, Feb group vs. Ben group. ^#P ≤ 0.05, ^##P ≤ 0.01, before vs. after treatment

ISSN: 1478-6362